Validity and Reliability of the Greek Pain Catastrophizing Scale
ConditionMigraine
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorNational and Kapodistrian University of Athens
About this trial
Migraine is a common neurological disorder that can significantly affect daily activities, quality of life, and emotional well-being. How individuals think and feel about pain may also influence their experience of migraine. Pain catastrophizing refers to an exaggerated negative response to pain, including persistent worry about pain and feelings of helplessness.
The Pain Catastrophizing Scale (PCS) is a commonly used questionnaire for assessing pain catastrophizing. However, the psychometric properties of the Greek version of the PCS have not been adequately evaluated in people with migraine.
This study aims to evaluate the validity and reliability of the Greek version of the Pain Catastrophizing Scale in patients with migraine. The study will determine whether the Greek PCS can be used as an appropriate tool for assessing pain catastrophizing in the Greek migraine population.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of migraine
Age 18-70 years
Ability to understand, read, write, and speak the Greek language
Disqualifiers
Presence of a headache disorder other than migraine
History of systemic diseases (malignant, inflammatory, acute traumatic, infectious, surgical, neurological, psychiatric, or rheumatological conditions)
Trial population
The study population will consist of adults aged 18-70 years with episodic or chronic migraine diagnosed by a neurologist according to the International Classification of Headache Disorders, 3rd edition (ICHD-3). Participants will be recruited from the Headache Outpatient Clinic of Aeginition Hospital, National and Kapodistrian University of Athens, Greece. Eligible participants must be able to understand, read, write, and speak Greek.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
130 Participants
are grouped into 1 trial groupGroup A: Patients with Migraine
Trial outcomes
Primary outcomes
1
Pain Catastrophizing Scale
The psychometric properties of the Greek version of the Pain Catastrophizing Scale (PCS) will be evaluated in patients with migraine. The PCS consists of 13 items scored from 0 (never) to 4 (always), with a total score ranging from 0 to 52. Higher scores indicate greater pain catastrophizing. Reliability will be assessed using internal consistency and test-retest reliability.
Time frame
Baseline and 7-14 days after baseline for test-retest reliability.Secondary outcomes
1
Migraine Disability Assessment
Migraine-related disability will be assessed using the MIDAS questionnaire. The total score is based on days of activity lost because of headache during the previous 3 months. Higher scores indicate greater migraine-related disability.
Time frame
Baseline2
Headache Impact
Headache-related impact on daily functioning and quality of life will be assessed using the HIT-6. Total scores range from 36 to 78, with higher scores indicating greater headache impact.
Time frame
Baseline3
Migraine-Specific Quality of Life
Migraine-specific quality of life will be assessed using the 14-item MSQv2.1, which includes Role Function-Restrictive, Role Function-Preventive, and Emotional Function domains. Scores are transformed to a 0-100 scale, with higher scores indicating better migraine-specific quality of life.
Time frame
Baseline4
Headache Pain Intensity
Headache pain intensity will be assessed using the VAS, ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.
Time frame
BaselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: